Document Detail

Antifibrotic effect of aloe vera in viral infection-induced hepatic periportal fibrosis.
MedLine Citation:
PMID:  22563189     Owner:  NLM     Status:  MEDLINE    
AIM: To investigate the anti-oxidative and anti-fibrotic effects of aloe vera in patients with liver fibrosis.
METHODS: Aloe vera high molecular weight fractions (AHM) were processed by patented hyper-dry system in combination of freeze-dry technique with microwave and far infrared-ray radiation. Fifteen healthy volunteers as the control group and 40 patients were included. The patients were randomly subdivided into two equal groups: the conventional group was treated with placebo (starch), and AHM group was treated with 0.15 gm/d AHM, both for 12 consecutive weeks. The patients were investigated before and after treatment. Serum activity of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), hyaluronic acid (HA), transforming growth factor-β (TGF-β) and matrixmetalloproteinase-2 (MMP-2) were determined. The reduced glutathione (GSH) and malondialdehyde (MDA) levels in liver were assayed and the expression of hepatic α-smooth muscle actin (α-SMA) was identified by immunohistochemistry.
RESULTS: At the start of the study, the hematoxylin and eosin staining revealed fibro-proliferated bile ductules, thick fibrous septa and dense inflammatory cellular infiltration in the patients before treatment. The use of AHM for 12 wk significantly ameliorated the fibrosis, inhibited the inflammation, and resulted in minimal infiltration and minimal fibrosis compared to the conventional group. The enzyme activities of the liver (ALT, AST and ALP) were attenuated after treatment in both groups, and the decrease in the AHM group was more significant as compared with the conventional group. Similar to the AST, the MDA levels were significantly higher before treatment, and were attenuated after treatment in both groups. In contrast, the hepatic glutathione content in the patients were decreased significantly in the AHM group compared to the controls. The serum levels of the fibrosis markers (HA, TGF-β and MMP-2) were also reduced significantly after treatment. The expression of α-SMA was modified in patients before and after treatment as compared with the normal controls. In the conventional group, there was only thin and incomplete parenchymal α-SMA positive septum joining the thickened centrilobular veins, while in the AHM group, few α-SMA positive cells were present in sinusoid and lobule after treatment.
CONCLUSION: Oral supplementation with AHM could be helpful in alleviating the fibrosis and inflammation of hepatic fibrosis patients.
Sahar K Hegazy; Mohamed El-Bedewy; Akira Yagi
Related Documents :
12472799 - Creation, cannulation and survival of arteriovenous fistulae: data from the dialysis ou...
16809889 - Frequency of hypoferritinemia, iron deficiency and iron deficiency anemia in outpatients.
20025679 - Efficacy of low-dose i.v. iron therapy in haemodialysis patients.
2009719 - The outcome of renal transplantation in children without prolonged pre-transplant dialy...
18552239 - Could solutions low in glucose degradation products preserve residual renal function in...
1680459 - Improved overall survival of elderly patients on peritoneal dialysis.
9159689 - Intraoperative and postoperative complications of high-frequency capsulotomy and contin...
17324829 - Topical pimecrolimus in the treatment of vitiligo.
8128459 - Video-assisted thoracoscopic surgery--indications, results, complications, and contrain...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  World journal of gastroenterology : WJG     Volume:  18     ISSN:  2219-2840     ISO Abbreviation:  World J. Gastroenterol.     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-05-07     Completed Date:  2012-09-18     Revised Date:  2014-05-20    
Medline Journal Info:
Nlm Unique ID:  100883448     Medline TA:  World J Gastroenterol     Country:  China    
Other Details:
Languages:  eng     Pagination:  2026-34     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Actins / analysis
Alanine Transaminase / blood
Aspartate Aminotransferases / blood
Glutathione / metabolism
Hepatitis B / complications*
Liver / pathology
Liver Cirrhosis / drug therapy*,  etiology
Middle Aged
Transforming Growth Factor beta / pharmacology
Reg. No./Substance:
0/ACTA2 protein, human; 0/Actins; 0/Transforming Growth Factor beta; EC Aminotransferases; EC Transaminase; GAN16C9B8O/Glutathione

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Stem cell differentiation and human liver disease.
Next Document:  Transactivation of the TIEG1 confers growth inhibition of transforming growth factor-?-susceptible h...